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Introduction 
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Tuberculosis (TB) in HIV-positive persons remains a great challenge for physicians 
globally. Survival rates of HIV-infected persons with active TB (HIV/TB patients) vary substantially 
around the world and depends on several factors relating to the management of both HIV 
infection and TB disease. Among such factors, the most important are: prompt and proper 
diagnosis of TB, including culture and resistance tests; timely initiation of adequate TB treatment, 
as well as assessment of a patient’s immune status and timely initiation of combination 
antiretroviral therapy (cART). (1;2) These factors are mainly related to and depend on the local 
level of health care and availability of resources. Incidence rates of TB among HIV- infected 
persons would naturally be higher in regions with a high prevalence of Mycobacterium 
tuberculosis (MTB) infection in the general population, while mortality rates are likely to be higher 
in settings with a high prevalence of multi-drug resistant (MDR) TB. (3-7) However, even in 
resource-limited settings with a high prevalence of TB it is possible to achieve a significant 
reduction in TB associated mortality among HIV/TB patients. (8;9) 
We have previously reported a number of patient characteristics relating to both HIV (i.e. 
having AIDS or poor immune status) and TB (i.e. having disseminated or rifamycin-resistant 
disease) were associated with an increased risk of death. In addition, some aspects reflective of 
patient care such as not including a rifamycin in first line TB therapy or not commencing cART 
were independent predictors of death. (6) These factors, however, could only partially explain 
regional differences in mortality, suggesting that other patient or health care associated factors 
may have differed between the geographic regions. 
The purpose of the current analysis was to evaluate the extent of appropriate health care 
provided to HIV/TB patients across different geographical regions by establishing a Health Care 
Index (HCI), and to use this HCI to generate an HIV/TB HCI score that reflects health care 
utilisation. We then analysed the cumulative probability of death in patients stratified by HCI score 
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and regional differences in hazards of death in multivariable models incorporating the HCI score.
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Methods 
Patient cohort 
The HIV/TB study is an international cohort of consecutive HIV-infected patients 
diagnosed with TB who initiated anti-TB treatment between January 2004 and December 2006 at 
one of the 52 participating clinics in Europe and Argentina. The present analysis is based on 1061 
HIV/TB patients whose HIV infection was diagnosed prior to or up to one month after TB diagnosis 
to avoid bias when assessing HIV management. Details of the study have been published 
elsewhere. (6) Briefly, information was collected retrospectively on a standardised case report 
forms (CRF) and included demographic and clinical characteristics of the TB disease, details of 
smear, culture and resistance tests performed, drug regimens used and TB outcomes. Information 
on the underlying HIV infection was collected on a separate CRF and included all available CD4-cell 
count and HIV-RNA measurements, use of antiretroviral drugs, presence of AIDS defining illnesses 
(other than TB) and use of chemoprophylaxis. (10) 
Health care index  
To evaluate aspects of TB and HIV health care, we chose a number of health care 
parameters that reflected the actual care provided to patients rather than disease specific 
characteristics (e.g. ‘having a culture or resistance test performed’ rather than ‘disease caused by 
drug resistant Mycobacterium tuberculosis’). These parameters were combined in a health care 
index, for which the following components were a priori considered: 
1. World Health Organization (WHO) defined definite diagnosis of TB: culture confirmed disease 
due to MTB and/or at least one sputum smear examination positive for acid-fast bacilli (AFB). 
(11) 
2. The undertaking of an MTB drug resistance test. 
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3. Inclusion of rifamycin (R), isoniazid (H) and pyrazinamide (Z) in the initial TB treatment 
regimen. 
4. Availability of at least one CD4-cell count measurement between 6 months prior to and 1 
month after TB diagnosis. 
5. Initiation of cART (combination of at least 3 antiretroviral drugs from any class) prior to or up 
to one month after TB diagnosis. 
The one month cut off for CD4-cell counts and use of cART was chosen to reduce survival 
bias as substantial early mortality was observed. In sensitivity analyses, we assessed the effects of 
initiation of cART within 3, 6, 3-9 and >9 months of TB diagnosis, and CD4-cell count 
measurements obtained within 2, 3 and 6 months of TB diagnosis 
Statistical analysis 
The study population was divided into four geographical regions according to the country 
of residence: EE (N=573), CNE (N=166), SE (N=208) and AR (N=114)1. Descriptive statistics were 
used to compare patient characteristics and the HCI components across regions. The HCI 
components were considered as quantitative discrete variables (Yes/No), and given a score of zero 
if no information was available for a given patient. The proportion of patients to whom each HCI 
component applied was calculated and compared by region. Follow-up was from the date of TB 
diagnosis till last clinic visit (or date of loss to follow-up), date of death or one year after TB 
diagnosis, whichever occurred first. TB was classified as pulmonary, if disease was limited to lungs 
and/or pleura; extrapulmonary, if TB was limited to any other single organ system; or 
disseminated, if it was miliary TB, TB in at least two organ systems, or if MTB had been isolated 
from blood or bone marrow. 
                                                 
1 Eastern Europe (EE): Belarus, Latvia, Romania, Russia, Ukraine; Central/Northern Europe (CNE): Denmark, France, 
Switzerland, United Kingdom; Southern Europe (SE): Italy, Spain; Argentina (AR) 
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To establish an HCI score, the relative hazard of death for each HCI component was 
calculated using a multivariable Cox model incorporating all 5 HCI components. A weighted score 
was then assigned to each significant HCI component based on the natural logarithm of its relative 
hazard of death. The mean HCI score was calculated for each region and compared to the 
proportion of patients who died within 12 months of TB diagnosis and to those with successful TB 
outcomes (cure/treatment completion). 
Kaplan-Meier survival analysis was used to estimate the probability of death within 12 
months of TB diagnosis among patients stratified by HCI score. Cox proportional hazard models 
were used to analyse the effect of the HCI score on mortality. Other factors included in the Cox 
model were those that were previously shown to be associated with mortality and included: 
gender, CD4-cell count at TB diagnosis, prior AIDS diagnosis, previous TB diagnosis, TB rifamycin 
resistance, and site of TB. (6) 
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Results 
Patient population 
A total of 1061 HIV/TB patients were included in the analysis. Patient characteristics are 
presented in Table 1. As reported previously, patients from EE were younger and more often had a 
history of injection drug use (IDU) and/or hepatitis C co-infection. (6) Approximately half of all 
patients had disseminated TB, and the majority of patients had established HIV infection at the 
time of TB diagnosis. Patients from AR had more profound immunodeficiency, while patients from 
EE had less advanced HIV infection. 
The proportion of patients with positive values for each HCI component differed 
significantly by geographic region (Table 1). Fewer patients in EE had a definite TB diagnosis, 
initiated RHZ-containing TB therapy or received cART. Patients in EE and AR less often had TB drug 
resistance tests and CD4-cell counts performed. 
Health care index score 
To develop an HCI score, the five selected components were included in a Cox model with 
death as the dependent variable (Table 2). Use of cART, RHZ-containing initial TB treatment and 
having a resistance test performed were associated with a reduced hazard of death in both 
univariable and multivariable models. The availability of a CD4-cell count and a definite TB 
diagnosis were not associated with a reduced hazard of death in either univariable or 
multivariable analysis (Table 2). Consequently, these components were not included in the final 
HCI score. Similar results were obtained when using different time windows for CD4-cell count 
measurements or cART initiation (data not shown). Of note,  having culture-based definite TB 
diagnosis (i.e. excluding patients with only positive smear tests) was highly correlated (R=82%, 
p<0.0001) with having resistance test performed. Including smear positive tests in the definite 
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diagnosis decreased this correlation to 62% and reduced the association between definite 
diagnosis and risk of death to an insignificant level. 
The natural logarithms of the three relative hazards (RH) of death were used to weigh the 
components that make up the HCI score. As the effects of initial treatment with RHZ and use of 
cART were approximately double the magnitude of the effect of resistance testing, resistance 
testing was assigned 1 point and the use of RHZ-containing initial TB treatment and use of cART 2 
points each. The HCI score could thus range from 0 to 5 with a higher score indicative of more 
intensive health care utilisation (Table 2). 
An HCI score was calculated for each patient. The distribution of HCI scores for each 
region is displayed in Figure 1. The majority (54-82%) of patients from CNE, SE and AR had HCI 
scores >3 compared with only 29% of patients from EE (p<0.0001), where 28% in EE had an HCI 
score of 0. The mean HCI score was highest in CNE (3.2 [95% CI 3.1-3.3]), followed by SE (3.0 [2.9-
3.2]) and AR (2.9 [2.6-3.0]), and was lowest in EE (1.6 [1.5-1.7]), p<0.0001. 
Health care index score and TB treatment outcome 
Treatment outcome was available for 995 (98%) patients. Overall, successful TB outcome 
was reported for 578 patients (58%) and commonest in regions with the highest HCI scores. 
Similarly, Kaplan-Meier estimates of being alive at 12 months were highest in regions with the 
highest HCI scores (Figure 2). A progressive reduction in 12 month cumulative mortality from 39% 
(95% CI: 31% - 48%) for patients with HCI = 0, to 9% (6% - 13%) for those with HCI ≥ 4 was 
observed (p<0.0001) (Figure 3). When the HCI score was incorporated in unadjusted Cox models of 
death within 12 months of TB diagnosis, a 38% reduction in mortality (RH 0.62 (95% CI 0.56 – 
0.70), p<0.0001) for each unit increase in HCI score was observed (Table 3). This association 
remained significant (RH 0.73 (0.64-0.84)) after adjustment for other factors that could potentially 
affect prognosis of HIV/TB patients (gender, CD4-cell count at TB diagnosis, prior TB or AIDS 
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diagnosis, rifamycin resistance, and site of TB) (Table 3). However, despite the significant 
predictive value of the HCI score, patients from EE remained at approximately 3-fold increased risk 
of death compared with the other regions after adjustment for HCI score. 
Sensitivity analyses 
A number of sensitivity analyses were performed (Table 3) to test the performance of the 
score in various subpopulations. Overall, the results of these analyses were consistent with the 
main finding that the HCI score was a significant predictor of one-year mortality in HIV/TB 
patients. For example, when restricting analysis to IDU patients (N=521) or patients from Eastern 
Europe (N= 573), a one unit increase in HCI score was associated with 24% and 27% reductions in 
mortality, respectively. In analysis restricted to patients with pan-susceptible TB (N=337), a one 
unit increase in HCI score was associated with a 27% reduction in mortality, although this was 
insignificant in the multivariable model likely due to the small sample size.  Furthermore, when 
restricting endpoints to only TB- and AIDS-related deaths (excluding deaths from any other 
causes), a one unit increase in HCI score reduced mortality by 15%. Finally, when the HCI score 
was included in the model as a categorical variable, one year mortality was 45% lower in patients 
with an HCI score of 1 and 72% lower in those with HCI scores of 4/5 compared with patients with 
an HCI score of 0 (Table 3). 
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Discussion 
In this study we assessed and compared health care utilization for HIV/TB patients by 
using a number of health care parameters. These parameters were further used to generate a HCI 
score as a measure of health care utilization. HCI score was predictive of mortality in HIV/TB 
patients. A one unit HCI score increase was independently associated with a 27% reduced risk of 
death within the first year after TB diagnosis. However, the observed regional differences in 
mortality among HIV/TB patients in Europe and Argentina were only partly explained by 
differences in health care utilization. While the use of RHZ-based anti-TB therapy, TB drug 
susceptibility testing and early use of cART are to be implemented as a priority, further research is 
required to explain the profound regional differences in HIV and TB outcomes and propose 
additional measures to harmonize these outcomes. 
The HCI score presented here can be implemented and used for two main purposes: 
evaluation and comparison of health care utilisation for HIV/TB patients and predicting patients’ 
prognosis. It can be implemented and assessed by health care authorities at various levels, from a 
single clinic to programme, country and region. Further, it can contribute to establishment of a 
benchmark of health care utilization for HIV/TB patients by identification a best performing 
facility. The advantage of this HCI score is that it includes a set of simple and widely used 
diagnostic and treatment procedures, which should be available in both high- and low-income 
settings. Our HCI score is based on the health care parameters that previously have been found to 
be independently associated with the outcome of HIV/TB patients (5;6;12). The predictive value of 
the HCI score remained highly significant when the model was adjusted for other factors that 
might play a role in patients’ outcome (Table 3), suggesting that this association is not a result of a 
confounding. 
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Optimal management of TB includes early case detection and initiation of effective anti-
TB therapy. Increased frequency of sputum-smear negativity in HIV-patients requires performance 
of culture test, which has been shown to be more sensitive in HIV/TB patients (13;14). Culture and 
drug resistance testing are essential in TB diagnosis to ensure effective therapy is administered, 
especially in settings with a high prevalence of MDR-TB. (15;16) Conventional culture and 
resistance testing are disadvantaged by advanced laboratory set-up and long incubation time. 
Early detection of resistant MTB strains is critical particularly in high prevalent MDR-TB settings in 
order to adjust treatment regimen and prevent transmission of drug-resistant strains. Thus, there 
is a critical need for diagnosis of TB to be more rapid and reliable and less costly, than is currently 
the case in many resource limited settings. (17-19) Rapid tests for simultaneous molecular 
detection of MTB and drug-resistant strains should be widely implemented and used. (17) 
As approximately 50% of our patients had disseminated TB, relying solely on sputum 
samples may not be sufficient to make a definite TB diagnosis and culture or molecular diagnostics 
of lymph node aspirates, blood or bone marrow may need to be more widely undertaken to 
obtain MTB isolates for drug susceptibility testing and thus fulfilling this HCI component. (20;21) 
Successful outcome of TB treatment relies on a treatment regimen of high quality drugs 
to which the MTB isolate is susceptible, given at the correct dose and for a sufficient duration. 
(1;21) WHO recommends that empiric anti-TB treatment should, as a minimum, include a 
rifamycin, isoniazid, and pyrazinamide (RHZ-based), with the addition of 2-3 second-line anti-TB 
drugs if resistance is suspected. (22) When results of drug-susceptibility testing become available, 
the regimen should be individualised accordingly. In our study, the use of RHZ-based regimens as 
initial TB therapy and outcome were strongly correlated, even after adjustment for region of 
residence. (6) While this may reflect clinicians’ decisions to avoid RHZ in patients with poor 
outcome such as those with significant liver injury (i.e. HCV coinfected) (23), universal 
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implementation of RHZ-based regimens to treat HIV/TB in EE is an inexpensive measure to 
improve patient outcomes. More importantly, if second line anti-TB drugs are added while the 
results of resistance tests are awaited, amplification of TB drug resistance in partially resistant 
MTB isolates may be avoided and transmission of drug-resistant TB reduced. Further research is 
needed to investigate underlying reasons for not initiating RHZ-based therapy in EE. 
Two recent studies have addressed the timing of cART in HIV/TB patients (24-26). Both 
studies provided evidence for early cART initiation in patients with CD4-cell counts <50 cells/mm3. 
In addition, the SAPIT study showed benefit from cART use during TB therapy rather than deferral 
of cART until TB treatment is completed, even in patients with CD4-cell counts >200 cells/mm3. 
We observed that few patients were receiving cART prior to TB diagnosis or up to one month after 
TB diagnosis, irrespective of region of residence, and many of our patients did not commence 
cART during TB treatment. Our HCI model suggests benefit from early cART use in HIV/TB patients, 
which is consistent with the results of the above clinical trials and provides support for the notion 
that all HIV/TB patients should start cART while still receiving TB therapy. For most patients, cART 
may be safely deferred until the end of the intensive TB treatment phase, although patients with 
low CD4-cell counts or other evidence of immunosuppression, and possibly those infected with 
MDR TB, should start cART at the earliest opportunity (within 2 weeks of starting anti-TB 
treatment) (25;26). In EE especially, this will require improved access to cART for marginal groups 
of the population (i.e. IDUs, prisoners, alcohol addicts, etc) and adherence support to those who 
start cART (27). Finally, when making decision to initiate cART in HIV/TB patients the benefits and 
risks should be carefully weighed for each individual patient considering potential toxicities and 
drug-drug interactions, probability of IRIS, adherence issues, etc. 
There are some limitations to this study. Due to the retrospective design, some data 
could be missed or not available for collection. In order to ensure the completeness of data 
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collection, an extensive quality assurance programme has been performed, which included queries 
to the sites and monitoring visits. We were able to define the HCI score using variables, measured 
within the study; however there are may be other variables, which we were not able to capture. 
Although we included health care parameters known to be associated with patients’ outcome 
(5;6;12), other factors including, e.g. prevalence of primary MDR-TB, use of second-line anti-TB 
drugs, presence of integrated HIV and TB services, may affect outcomes. Future studies are 
needed, designed around these factors to enable identification of measures that may further 
improve HIV/TB outcomes, particularly in EE. Experience from South Africa has shown that 
integration of HIV and TB services helps to improve patients’ management and thus survival. (28) 
Health care infrastructure differs in Eastern Europe and is characterised by separate management 
of HIV and TB in different hospitals by different specialists, where the collaboration and data 
exchange may not be well developed. A sensitivity analysis including only patients from Eastern 
Europe, showed results consistent with the main analysis: a higher HCI score was associated with 
improved survival. The HCI score also did not change when models were stratified by an individual 
centre or country (data not shown). The HCI score needs to be validated in independent cohorts of 
HIV/TB patients in Europe and elsewhere. This is planned in a prospective extension of the HIV/TB 
study, which has now been initiated (www.cphiv.dk). 
HIV/TB programmes in developing world are encouraged to implement service 
integration, drug susceptibility testing and early cART initiation in HIV/TB patients. (29) The HCI 
score presented here may serve as a tool to predict the benefits of such interventions. Further 
refinement of the health care parameters, for instance by adding additional components, e.g. 
HIV/TB-service integration, duration of TB treatment, treatment changes according to the TB drug-
resistance patterns, use of directly observed therapy, use of co-trimoxazole prophylaxis, and 
adherence may enhance its clinical usefulness. 
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Conclusions 
We developed a HCI score which reflects health care utilisation in HIV/TB patients and 
which predicts outcome. The HCI is easy to apply in both high- and low-income settings, and if 
validated in other populations, may assist the planning of programmatic interventions. Our results 
suggest that the outcome of HIV/TB patients may be improved by implementing several measures, 
including MTB drug susceptibility testing, use of RHZ-based anti-TB therapy and early use of cART.
 
15 
 
Table 1. Baseline characteristics and health care index components in HIV/TB patients stratified by geographical region 
 
Eastern Europe 
N = 573 
Southern Europe 
N = 208 
Central Northern 
Europe 
N = 166 
Argentina 
N = 114 
P 
Patient characteristics   N, % 
Male gender  410 (71.6) 160 (76.9) 78 (47.0) 73 (64.0) <0.0001 
IDU (as risk factor for TB) a 409 (71.9) 63 (34.6) 19 (13.0) 30 (26.6) <0.0001 
Hepatitis C AB positive b 268 (46.9) 53 (25.5) 15 (9.0) 15 (13.2) <0.0001 
Disseminated TB c 349 (60.9) 104 (50.0) 86 (51.8) 57 (50.0) <0.0001 
Rifamycin resistant TB d 121 (45.8) 5 (3.5) 5 (4.5) 6 (16.2) <0.0001 
Prior AIDS e 79 (13.8) 42 (20.2) 22 (13.3) 63 (55.3) <0.0001 
  Median (IQR)      
Age, years 30.2 (26.2 – 35.0) 37.7 (31.8 – 43.5) 37.4 (31.6 – 44.2) 35.5 (30.2 – 41.7) <0.0001 
CD4-cell count, cells/l f 210 (85 – 463) 132.5 (46 – 291) 140 (50.5 – 293.5) 92 (40 – 233.5) <0.0001 
HIV-RNA, log10 copies/ml g  5.1 (4.3 – 5.7) 4.9 (3.5 – 5.6) 4.9 (3.4 – 5.6) 4.6 (3.5 – 5.4) 0.023 
Health Care Index components (N, %)  
Definite TB diagnosis 389 (67.9) 167 (80.3) 136 (81.9) 82 (71.9) 0.0002 
Resistance test performed h 264 (84.9) 141 (87.6) 111 (85.4) 37 (69.8) <0.0001 
RHZ-containing initial TB treatment 258 (45.0) 163 (78.4) 146 (88.0) 96 (84.2) <0.0001 
CD4-cell count measurement performed 
from 6 months prior to 1 month after TB 
diagnosis 
316 (55.2) 161 (77.4) 126 (75.9) 67 (58.8) 
<0.0001 
cART started prior to or within 1 month of TB 
diagnosis 
98 (17.1) 112 (53.9) 87 (52.4) 54 (47.4) 
<0.0001 
Footnote Table 1 
Eastern Europe (EE): Belarus, Latvia, Romania, Russia, Ukraine; Central/Northern Europe (CNE): France, Denmark, Switzerland, United 
Kingdom; Southern Europe (SE): Italy, Spain; Argentina (AR)  
Baseline defined as the date of TB diagnosis 
(a) TB risk factor was unknown for 51 patients: EE 4 (7.8%), SE 26 (51.0%), CNE 20 (39.2%), AR 1 (2.0%), p<0.0001 
(b) Hepatitis C antibody (AB) status was unknown for 528 patients No significant differences comparing the proportions with unknown 
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HCV AB status across the regions, p=0.13 
 
 
(c) Disseminated TB - TB involving more than one organ-system, miliary TB, or Mycobaterium tuberculosis isolated from blood or bone marrow 
(d) Proportion of those with resistance test performed  
(e) AIDS defined using the 1993 Centers for Disease Control and Prevention clinical case definitions (category C).  
(f) CD4-cell count was unknown for 208 patients: EE 146 (25.5%), SE: 14 (6.7%), CNE 22 (13.3%), AR 26 (22.8%), p<0.0001 
(g) HIV-RNA was unknown for 547 patients: EE 467 (81.5%), SE 23 (11.1%), CNE 11 (6.6%), AR 46 (40.4%), p<0.0001 
(h) Proportion of those with positive culture for Mycobaterium tuberculosis (N with culture confirmed TB 311, 161, 130, 53 in EE, SE, CNE 
and AR respectively) 
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Table 2. Cox proportional hazard model used to calculate the weighted Health Care Index (HCI) score 
 
HCI component  Univariable Multivariable Final Ln RH* HCI Score 
weighting 
 RH 95% CI p RH 95% CI p RH 95% CI p   
Definite diagnosis 0.76 0.54 – 1.05 0.097 1.18 0.79 – 1.78 0.42     0 
Resistance test performed  0.63 0.47 – 0.86 0.0031 0.65 0.45 – 0.95 0.025 0.71 0.53 – 0.97 0.031 -0.34  1 
Initial TB treatment with RHZ 0.37 0.28 – 0.51 <0.0001 0.41 0.30 – 0.57 <0.0001 0.43 0.31 – 0.58 <0.000
1 
-0.85 2 
CD4 measured from 6 months prior 
to or up to 1 month after TB 
diagnosis 
0.90 0.66 – 1.23 0.50 1.22 0.89 – 1.68 0.21     0 
cART started prior to or up to 1 
month after TB diagnosis 
0.32 0.21 – 0.48 <0.0001 0.35 0.23 – 0.53 <0.0001 0.36 0.24 – 0.55 <0.000
1 
-1.02 2 
 
*Ln (natural logarithm) RH (relative hazard) is calculated from the RHs of death obtained in the final model 
Absence of a HCI component yielded a zero score. The HCI score was calculated for each patient as the sum of each of the HCI 
components. 
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Figure 1. Distribution of patients according to health care index (HCI) score and region of residence 
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EE, Eastern Europe; SE, Southern Europe; CNE, Central/Northern Europe; AR, Argentina 
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Figure 2. Mean Health Care Index score and outcomes in HIV/TB patients stratified by region of residence 
 
 
Mean HCI score (95% CI): Eastern Europe (EE) 1.63 (1.52 – 1.74); Southern Europe (SE) 3.03 (2.88 - 3.18); 
Central/Northern Europe (CNE) 3.22 (3.09 – 3.34); Argentina (AR) 2.83 (2.64 – 3.02) 
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Figure 3. Kaplan-Meier probability of death in patients stratified according to their HCI score  
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Table 3. Univariable and multivariable relative hazard (RH) of death within 12 months of TB diagnosis 
 Univariable Multivariable 
Not including HCI score Including HCI score 
RH (95% CI) p RH (95% CI) P RH (95% CI) p 
Health care index score (per 1 unit increase) 0.62 (0.56 – 0.70) <0.0001   0.73 (0.64 – 0.84) <0.0001 
Region 
Eastern Europe   1.00  1.00    1.00  
Southern Europe 0.14 (0.07 – 0.28) <0.0001 0.13 (0.06 – 0.25) <0.0001 0.19 (0.09 – 0.39) <0.0001 
Central/Northern Europe 0.16 (0.08 – 0.32) <0.0001 0.17 (0.08 – 0.35) <0.0001 0.27 (0.13 – 0.58)  0.0007 
Argentina 0.28 (0.14 – 0.54) 0.0002 0.22 (0.11 – 0.45) <0.0001 0.31 (0.25 – 0.64)  0.0015 
Sensitivity analyses 
HCI Score (per 1 unit increase) in:       
- Patient with pan-susceptible TB, N=337 0.70 (0.50-0.97) <0.032   0.73 (0.50-1.07) 0.10 
- Injecting Drug users, N=521 0.69 (0.60-0.80) <0.0001   0.76 (0.66-0.87) 0.0004 
- Patients from Eastern Europe, N=573 0.76 (0.67-0.87) <0.0001   0.73 (0.64-0.84) <0.0001 
Only including TB- and AIDS-related deaths 0.83 (0.73-0.94) 0.0044   0.85 (0.73-0.99) 0.042 
Score 
0    1.00       1.00  
1 0.70 (0.45-1.10) 0.12   0.55 (0.35-0.86) 0.0082 
2 0.50 (0.33-0.76) 0.0010   0.57 (0.38-0.85)      0.0064 
3 0.33 (0.21-0.50) <0.0001   0.40 (0.25-0.63) 0.0001 
> 4 0.09 (0.05-0.19) <0.0001   0.28 (0.16-0.49) <0.0001 
 
Multivariable model adjusted also for gender, CD4-cell count at TB diagnosis (below or above 200 cells/mm3), prior AIDS, previous 
diagnosis of TB, presence of Mycobacteria strains resistant to at least rifampicin, location of TB (pulmonary, extrapulmonary, 
disseminated 
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